A protocol of randomized controlled trial for Modified Xiaoyao Powder in the treatment of chronic obstructive pulmonary disease combined mild to moderate depressio
- Conditions
- depression
- Registration Number
- ITMCTR2000004186
- Lead Sponsor
- Hospital of Chengdu University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Aged 18 to 65 years men and women;
2. Patients who had received a diagnosis of COPD combined mild to moderate depression (HAMD-17 score 7 to 24) and meet the syndrome of stagnation of liver qi of depression;
3. The course of depression does not exceed 3 months;
4. The patients has not taken antidepressants in the past 1 month;
5. Agree to participate and sign an informed consent form.
1. A history of a suicide attempt treament-resistant depression, and familial mental illness;
2. Had a recent history of other acute or chronic significant clinical manifestations medical conditions;
3. A history of bipolar disorder, schizophrenia, or schizo affective disorder;
4. Patients who cannot actively cooperate with the treatment.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the change in the HAMD-17 score from baseline;
- Secondary Outcome Measures
Name Time Method a reduction of more than 50% from baseline in the HAMD-17 score;the change from baseline in CAT score;the change from baseline in mMRC score;the frequency of hospitalizations;the number of exacerbations;